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Abstract The V3 region of HIV-1 envelope protein possesses a
single N-linked sugar chain, which is conserved in most HIV-1
strains. We studied its role in the life cycle of HIV-1 strains with
different co-receptor usage. Removal of the glycan appeared to
cause a marked reduction of CXCR-4- but not CCR-5-dependent
virus entry. A basic amino acid substitution at the 11th position
of V3 markedly compensated for the removal of the N-glycan.
These results indicate that the N-glycan plays an important role
for CXCR-4-dependent virus entry and that this role is exerted in
a particular context of the peptide backbone.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The envelope protein (Env) of human immunode¢ciency
virus type 1 (HIV-1) consists of the surface gp120 subunit
and the transmembrane gp41 subunit, which are non-cova-
lently associated with each other [1^3]. As many as some 30
N-asparagine-linked carbohydrate attachment sites were pre-
dicted in the Env amino acid sequence and actual attachment
of sugar chains appears to modulate the viral biological prop-
erties, infectivity and antigenicity [1^9]. However, the func-
tional signi¢cance of each of the glycans for viral activities
is not fully elucidated.
The infectivity, cellular host range and cytopathogenicity of
HIV-1 vary from strain to strain. Primary HIV-1 isolates ob-
tained from individuals at an early asymptomatic stage can
replicate in phytohemagglutinin-stimulated peripheral blood
mononuclear cells (PBMC) and primary macrophages but
not in established T cell lines. They are referred to as macro-
phage tropic (M-tropic) strains. On the other hand, the iso-
lates from about 50% of patients at a late disease stage rep-
licate in established T cell lines but not in macrophages, and
are thus termed T-cell-line tropic (T-tropic) strains. Recently,
chemokine receptors such as CXCR-4 and CCR-5 were iden-
ti¢ed as co-receptors that mediate fusion between the viral
envelope and the host cell membrane and facilitate the entry
of HIV-1 into cells following viral attachment to the major
receptor CD4 [10^16]. Di¡erences in cell tropism among HIV-
1 strains are now explained by di¡erent co-receptor usage.
CCR-5 is used by M-tropic strains [10,12^15], whereas
CXCR-4 is used by T-tropic strains [11,16]. The third variable
(V3) loop in gp120 has been found to be an important deter-
minant for virus cellular host range [17^19], and its basic
amino acid substitutions at positions 11 and/or 25 are closely
associated with the T-tropic phenotype [20^24].
The V3 loop contains a site for N-glycosylation at the 6th
position which is conserved in most HIV-1 strains but the
signi¢cance of this high degree of conservation has been
poorly addressed. To our knowledge, it has only been shown
that the N-glycan in the V3 of some T-tropic strains (HXB2,
HXB10, LAI and BRU) may be dispensable for virus infec-
tivity [4^8]. But removal of this N-glycan enhanced the virus
sensitivity to neutralizing antibodies, suggesting its role in
masking the potential antigenicity of V3 peptide [5^8]. Here,
we re-evaluated, by site-speci¢c mutagenesis, the signi¢cance
of this N-glycan of HIV-1 strains with various cell tropisms.
Contrary to the above reports, our data show that removal of
the N-glycan from V3 impaired e⁄cient virus replication. This
impairment appeared to be associated with a reduced level of
CXCR-4-dependent fusion and virus entry. Therefore, our
data suggest the importance of the highly conserved V3 N-
glycan not only for the antigenicity of HIV-1, but also for
viral infectivity and cellular host range. However, no such
requirement of the glycan has been found for CCR-5-depend-
ent fusion and virus entry characteristic of M-tropic strains.
Thus, there appear to be considerable strain-speci¢c di¡eren-
ces in the structure-functional relationships in HIV-1-co-
receptor interactions.
2. Materials and methods
2.1. Generation and propagation of N-glycosylation mutant viruses
Mutant DNA constructs of infectious molecular clones of HIV-1
strains NL43 [25], SF13 [26] and SF162 [27] were generated by site-
directed mutagenesis by the polymerase chain reaction (PCR)-medi-
ated overlap primer extension method [28]. Infectious viruses were
recovered by transfection of the mutant proviral DNA into SW480
cells, followed by cocultivation with PBMC as described previously
[24]. Virus production was determined by quantitative p24 enzyme-
linked immunosorbent assay (ELISA) and 50% tissue culture infec-
tious doses (TCID50) after 2 weeks. Infection of cells with wild-type
and mutant viruses was performed as described previously [24].
2.2. HIV-1 binding and entry assays
MT4 cells were treated with polybrene for 30 min and then exposed
to the wild-type or mutant viruses equivalent to 100 ng of p24 in
amount. The amount of virions bound to cells during 1 h at 4‡C
was quantitated by the p24 ELISA. The cells bound with virions
were subsequently incubated at 37‡C for 1 h to allow them to enter
the cells, and intracellular p24 antigen was quantitated after trypsiniz-
ing the cells to digest and eliminate the viruses remaining on the cell
surface [29].
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2.3. Generation of recombinant vaccinia viruses and
immunoprecipitation of HIV-1 envelope proteins
The human CCR-5 gene was PCR ampli¢ed from the total DNA
extracted from PBMC of a normal seronegative donor. A recombi-
nant vaccinia viruses (Vac) expressing CCR-5 or those expressing
mutant Env under the control of the vaccinia virus early/late pro-
moter for 7.5 kDa protein were generated using standard techniques
as described previously [30,31]. Immunoprecipitation of Env expressed
by the recombinant Vac was performed as described previously [32].
2.4. Generation of recombinant Sendai viruses expressing gp120
mutants and CD4 binding assay of the gp120
The gp120 genes of mutant NL43 clones were ampli¢ed by PCR
and introduced to the plasmid pV(3)SeV18+b(+) which had been
designed to generate a full-length Sendai virus (SeV) antigenome
RNA with an insertion of a foreign gene at the ¢rst locus [33^35].
From the plasmids, recombinant Sendai viruses were recovered ac-
cording to previously described procedures [33^36]. CD4 binding as-
say of the gp120 expressed from these recombinant viruses was per-
formed as described previously [34].
2.5. Gene reporter fusion assay
A Vac-based gene activation assay using the L-galactosidase (L-gal)
gene as a reporter was performed in L cells, a mouse ¢broblast line, as
described previously [37]. CCR-5 was expressed by Vac and CXCR-4
by SeV (Hu et al., in press). Data points were means of duplicate
assays.
3. Results
3.1. The e¡ect of silencing N-glycosylation in the V3 loop on
the biochemical and biological properties of the envelope
protein of strain NL43
The HIV-1 strain NL43 is a T-tropic strain that has been
well characterized. We replaced the canonical N-glycosylation
motif, Asn-Asn-Thr (NNT), in V3 of its Env with His-Asn-
Thr (HNT). We then created recombinant vaccinia viruses
expressing the wild-type and mutant (HNT) Env to determine
whether or not the mutation a¡ects the levels of expression of
gp160 and its processing to gp120 and gp41. BHK cells in-
fected with the respective recombinant vaccinia viruses were
labeled with [35S]methionine and then lysed for immunopreci-
pitation. The gp160, gp120 and gp41 were clearly detected in
comparable amounts in the two cell lysates (Fig. 1A). gp120
was detected solely in the culture supernatants again in com-
parable amounts (Fig. 1A). The HNT gp120 migrated slightly
faster than the wild-type gp120. This strongly suggests that
the V3 glycosylation site was actually used in the wild-type
and indeed silenced by the mutagenesis.
We then compared CD4 binding capacity of the mutant
gp120 with that of the wild-type gp120. For this experiment,
we produced the gp120 by a SeV vector, which was previously
shown to be extremely powerful in producing large quantities
of gp120 of NL43 [34]. Here the HNT gp120 was also ex-
pressed at a high e⁄ciency by the recombinant SeV. The
results clearly show that the HNT gp120 bound to the surface
of CD4-positive MT4 cells (Fig. 1B) and further hindered the
access of an anti-CD4 antibody to the surface (Fig. 1C), as
e⁄ciently as the wild-type gp120 did. Therefore, removal of
the N-glycan from V3 did not a¡ect the CD4 binding capacity
of gp120.
The fusion activities of the wild-type and HNT Env, ex-
pressed from the respective recombinant vaccinia viruses,
were compared in the context of di¡erent co-receptors by a
fusion assay using a L-gal gene as a reporter. Immunopreci-
pitation assays as shown in Fig. 1A were always included to
assess comparable levels of expression of the wild-type and
mutant glycoproteins in each fusion study. As shown in Fig.
1D, the fusion activity of HNT Env was consistently found to
be about 30% of that of the wild-type, when CXCR-4, a co-
receptor for T-tropic strains of HIV-1, was used. No CCR-5-
dependent fusion was observed for either of the glycoproteins.
To rule out the possibility that the impaired fusion activity
was due to the amino acid substitution itself rather than the
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Fig. 1. A: Immunoprecipitation analysis of BHK cells infected with
recombinant vaccinia viruses expressing HNT, NNI and wild-type
Env proteins of strain NL43. WR indicates infection with the wild-
type vaccinia virus strain WR. Infection was initiated with an input
multiplicity of 10 plaque-forming units per cell and cells were har-
vested at 20 h after infection. B: FACS analysis of gp120 binding
to CD4 expressing MT4 cells. C: Blocking of anti-CD4 antibody
(Leu3a) binding to MT4 cells pretreated with various amounts of
wild-type or HNT gp120. Data points are means þ standard devia-
tion of triplicate samples. In experiments B and C, the culture
supernatant of CV-1 cells infected with recombinant Sendai virus
was used as the source of each gp120 [34]. D: Quantitation of fu-
sion activities of Env proteins of the wild-type, mutant HNT and
NNI, expressed from the respective recombinant vaccinia viruses
(Env/Vac). Either CXCR-4 or CCR-5 was expressed as a co-recep-
tor.
Fig. 2. A: Growth kinetics of the wild-type NL43 (b) and
NL43HNT (a) in MT4 cells. Infection was initiated with 50 TCID50
per culture of each virus. B: HIV-1 binding and entry assays. MT4
cells were incubated with viruses (100 ng of p24) and the virus entry
was determined by the percentage of p24 amount within cells in the
total p24 bound to the cell surface as described in Section 2.
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loss of the N-glycan, we generated a second mutant Env,
NNI, in which an isoleucine residue was substituted for the
third position threonine in the canonical N-glycosylation sig-
nal. As shown in Fig. 1A, the NNI gp160 was expressed and
processed as e⁄ciently as the wild-type or HNT gp160. Sim-
ilar to HNT gp120, the NNI gp120 migrated a little faster
than the wild-type (Fig. 1A), and CXCR-4-dependent fusion
activity was also impaired (Fig. 1D). These results strongly
suggest that the removal of the N-glycan from V3 rather
than the speci¢c amino acid substitutions impaired the fusion
activity of NL43 Env.
3.2. E¡ect of the removal of V3 glycan on the replication
capability of NL43 virus in MT4 cells
We then generated viruses which contained the above de-
scribed mutations in the V3, and compared their replication in
MT4 cells. Hereafter, the mutant viruses are referred to as
NL43HNT and NL43NNI, and the wild-type virus simply
as NL43. NL43HNT (Fig. 2A) as well as NL43NNI (not
shown) were found to grow more slowly than the parental
NL43 virus, when infection was initiated with 50 TCID50
per culture. These data suggest that the removal of the N-
glycan caused signi¢cant loss of viral replication capability
in MT4 cells. We have to note that when higher input virus
doses (e.g. 5000 TCID50 per culture) were used, di¡erences
between NL43 and NL43HNT or NL43NNI were not well
resolved (data not shown), suggesting that the e¡ect of glycan
removal would be small in a single round of replication and
became appreciable only after numerous rounds of replica-
tion. We further compared NL43HNT and NL43 with respect
to virus binding to and entry into cells. We found that the
amount of p24 bound to cells £uctuated considerably from
experiment to experiment, allowing no exact direct compari-
son. However, the ratios of amount of virus that entered cells
to that bound to cells were constant for each virus. The per-
centages of p24 amounts within cells in the total p24 amounts
bound to cell surface indicated consistently that the entry
e⁄ciency was lower for NL43HNT than for NL43 (Fig.
2B). These data suggest that NL43HNT was impaired in pen-
etration capability and appeared to be compatible with the
reduced fusion activity of HNT Env (Fig. 1D).
3.3. Association of an N-glycan loss in the V3 loop with a
basic amino acid substitution at the 11th position in
natural isolates
Although our data suggesting the functional importance of
V3 N-glycan appear to rationalize its conservation in a wide
variety of HIV-1 isolates, a small portion of strains were re-
ported to lack the N-glycan [21,38]. Fig. 3A shows V3 amino
acid sequences lacking the N-glycosylation site of HIV-1 sub-
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Fig. 3. V3 amino acid sequences of HIV-1 (subtype B) that were
previously reported to be devoid of the glycan [38,42^45] (A), deter-
mined here or previously [24,46] with sera of four infected individu-
als (#20, #99, #10 and #76) (B) and of the viruses used in this
study (C). Dashes in B indicate sequence identity to the respective
top sequences with an N-glycan. The N-linked glycosylation signal
(NNT) is boxed and residues at positions 11 and 25 are surrounded
by ellipses. The basic amino acid residues at position 11 and 25 are
shaded. D: Replication of NL43HNT (a), NL43HNTR (E) and the
wild-type NL43 (b) in MT4 cells.
Fig. 4. A: Replication of the wild-type SF13 and SF162 (b) and
their glycosylation mutants SF13NNI and SF162NNI (a) in
PBMC, MT4 cells and primary macrophages. B: CXCR-4- and
CCR-5-dependent fusion activity of the wild-type and mutated enve-
lope glycoproteins expressed from vaccinia viruses (Env/Vac).
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type B strains to which the NL43 strain belongs. In Fig. 3B,
V3 sequences obtained from sera of four HIV-1-infected in-
dividuals are shown, which reveal the presence of a mixture of
V3 sequences with and without the N-glycan. A strong corre-
lation was observed between the lack of the N-glycan and a
basic amino acid substitution at the 11th position (Fig. 3A,B).
Inspection of 279 reported sequences of V3 of HIV-1 subtype
B [21,39] further revealed that 33% of the sequences carrying a
basic amino acid residue at the 11th position lack the N-gly-
can, whereas only 5% of those carrying a non-basic amino
acid residue at this position lack the glycan. This di¡erence
is statistically signi¢cant (P6 0.001). On the other hand, there
is no such correlation between the loss of N-glycan and basic
amino acid substitution at the 25th position.
NL43 and its derivatives used in the present study possess a
non-basic serine residue (S) at the 11th position. We substi-
tuted an arginine residue (R) for the S in the glycosylation-
negative NL43HNT mutant, generating NL43HNTR (Fig.
3C). The replication capability in MT4 cells was found to
be restored not completely but markedly by this additional
mutation (Fig. 3D). These data suggest that a basic amino
acid substitution at the 11th position compensated at least
partially for the loss of V3 N-glycan.
3.4. The e¡ect of N-glycosylation site mutations on HIV-1
strains with di¡erent cellular host ranges
HIV-1 displays strain-dependent di¡erences in cellular host
range. Since V3 is one of the major determinants for the viral
cellular host range [17^19], we also introduced mutations to
silence the N-glycosylation of V3 of HIV-1 strains with di¡er-
ent cell tropisms. The strains used were the M-tropic SF162
and dual tropic SF13. The glycosylation signal NNT in their
V3 was replaced with NNI, and the infectious viruses recov-
ered from the respective mutagenized cDNA were named
SF162NNI and SF13NNI.
The wild-type and mutant viruses were compared for rep-
lication capability in PBMC, human primary macrophages
and MT4 cells (Fig. 4A). In PBMC, SF162NNI grew as e⁄-
ciently as the wild-type SF162, whereas the replication of
SF13NNI was retarded compared with SF13. In MT4, SF13
grew well to a high titer, whereas SF13NNI replication was
severely impaired. On the other hand, no or only a marginal
di¡erence was found in replication capability in primary mac-
rophages between SF162NNI and SF162 or between
SF13NNI and SF13. These data suggest that the removal of
an N-glycan from V3 severely a¡ected the T-tropism but not
the M-tropism of HIV-1.
3.5. The co-receptor-dependent fusion activity of the envelope
proteins of SF13NNI and SF162NNI
Co-receptor-dependent fusion was studied by Vac-based ex-
pression of the Env of SF162, SF13 and their derivatives (Fig.
4B), as described above for the T-tropic strain NL43 Env and
its derivatives. As expected, the dual tropic SF13 Env could
use both CXCR-4 and CCR-5 in cell fusion, while M-tropic
SF162 Env could use CCR-5 but not CXCR-4. CXCR-4-de-
pendent fusion activity of SF13NNI Env was about 50% of
that of SF13 Env, whereas CCR-5-dependent fusion activity
of SF13NNI Env was nearly the same as that of SF13 Env.
No appreciable reduction of CCR-5-dependent fusion activity
was observed for SF162NNI Env compared with the parental
SF162 Env. These data, together with those presented in Fig.
1D, suggest that the removal of the N-glycan from V3 a¡ects
the CXCR-4-dependent but not CCR-5-dependent fusion. It
appeared that the removal of the glycan converted the dual
tropic SF13 to a nearly M-tropic virus (Fig. 4A). Consistent
with this notion, SF13NNI became sensitive to L-chemokine
MIP-1 L, a natural ligand of CCR-5, while SF13 was resistant
to this chemokine possibly because of preservation of the in-
fection route via CXCR-4 (data not shown).
4. Discussion
In the present study, we generated N-glycosylation mutants
of HIV-1 strains which di¡er in their cellular host range and
demonstrated that the removal of the N-glycan from V3 im-
paired replication capability of a T-tropic HIV-1. The same
mutation caused no such impediment for an M-tropic strain.
The speci¢city of co-receptor usage of each mutant Env was
con¢rmed by a Vac-based fusion assay, which demonstrated
that the mutation a¡ected CXCR-4-dependent fusion but not
CCR-5-dependent fusion. Co-receptor-speci¢c requirement of
the N-glycan was further supported by similar mutagenesis of
a dual tropic strain, as removal of the glycan a¡ected the use
of CXCR-4 but not CCR-5.
Previously, the N-glycan in V3 of HXB2, HXB10, LAI and
BRU strains was reported to be dispensable for their infectiv-
ity to T cell lines, although detailed growth kinetics and ex-
perimental conditions were not described [4^8]. The experi-
ments appear to have been done by infection initiated with
only a single virus dose that was not speci¢ed clearly. We
have to note that di¡erences between the wild-type and
mutant viruses were not observed with higher input virus
doses, suggesting that the e¡ect of glycan removal would es-
sentially be small in a single step replication, and become
appreciable only after numerous rounds of replication. Even
though small to a single replication cycle, the contribution of
the glycan would be great enough to in vivo pathogenesis
which involves persistence of highly active viral replications
for a long period.
It was previously noted that the N-glycosylation site in V3
is less conserved among T-tropic isolates than among M-
tropic isolates [5]. This is apparently paradoxical if the N-
glycan is important for CXCR-4- but not CCR-5-dependent
entry as proposed in this study. However, inspection of V3
sequences revealed that the loss of the N-glycan is closely
associated with a basic amino acid substitution at the 11th
position. Furthermore, the basic amino acid substitution at
the 11th position in NL43HNT partially but signi¢cantly re-
stored the infectious capacity. Therefore, the N-glycan in V3
seems to be dispensable only in the particular context of the
peptide backbone, and plays an important role for CXCR-4-
dependent membrane fusion when the 11th position of V3 is
occupied by a non-basic residue.
On the other hand, removal of the N-glycan from the V3
loop was reported to increase V3-speci¢c antigenicity [5^8].
We could con¢rm this since the NL43HNT showed increased
sensitivity to the V3-speci¢c neutralizing monoclonal antibody
902 (data not shown). Back et al. [5] further raised the view
that the N-glycan protects the V3 loop from attack by anti-
bodies and hence is dispensable in patients with compromised
immunity. However, in view of our present data showing a
functional requirement of the glycan, the situation does not
appear to be that simple. Their view may be applicable only to
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M-tropic strains whose N-glycan in V3 does not appear to be
functionally important.
The V3 loop was suggested to be involved in the gp120-co-
receptor interaction [40,41]. Our present study demonstrated
that there is a strain-speci¢c requirement of the V3 glycan for
this interaction. It is interesting but di⁄cult to explain why
and how the V3 glycan contributes to the infection process
dependent on CXCR-4 but not CCR-5. It was previously
reported that a subtle charge change in V3 of the T-tropic
HIV-1 strain SF2 caused a drastic reduction of viral replicat-
ing capability in T cell lines, whereas the corresponding
charge change in the M-tropic strain SF162 did not a¡ect
macrophage tropism [18]. It is thus possible that the V3 of
T-tropic strains should be structurally more stringent for co-
receptor recognition than that of M-tropic strains, and there-
fore the removal of N-glycan from the former could make an
impact on virus-co-receptor interaction and infectivity.
The N-glycan on V3 is supposed to be a complex type and
thus negatively charged [1]. A single N-linked sugar chain
possesses a molecular mass of 2000^3000. These physical
and structural properties may somehow be required for V3
to fully interact with CXCR-4. However, the sugar chain
may not be directly involved in the interaction, since a basic
amino acid substitution at a nearby site partially compensated
for the loss of the glycan. It is puzzling if the presence of a
negative charge (in the glycan) and a basic amino acid sub-
stitution for a neutral nearby residue are both factors leading
to upregulation of CXCR-4-dependent fusion. Increase of hy-
drophilicity is a common feature shared by both. V3 glyco-
sylation and the basic amino acid substitution may thus facil-
itate V3 exposure for better interaction with CXCR-4. In any
case, a basic amino acid substitution at the 11th position
appears to be an apt change in vivo for this particular N-
glycan-negative virus to acquire a su⁄ciently high infectivity
or for the virus to evade clearance due to infectivity reduction
caused by spontaneous removal of the glycan.
In summary, our data indicate for the ¢rst time that a sugar
chain at a speci¢c position of the HIV-1 envelope glycoprotein
is required for a specialized function to initiate infection. With
respect to the V3 loop of HIV-1, numerous structure-function
studies have been done using synthetic peptides without the
sugar chain. Such studies may be able to dissect only a part of
the natural reaction or may sometimes produce misleading
results.
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